Zynerba Pharmaceuticals (ZYNE) Hits New 12-Month High at $13.63

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)’s share price reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $13.63 and last traded at $13.51, with a volume of 1643695 shares changing hands. The stock had previously closed at $12.94.

ZYNE has been the topic of several research reports. ValuEngine downgraded Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, February 4th. Roth Capital initiated coverage on Zynerba Pharmaceuticals in a research report on Tuesday, April 30th. They issued a “buy” rating and a $36.00 target price on the stock. Cantor Fitzgerald reissued a “buy” rating and issued a $11.00 target price on shares of Zynerba Pharmaceuticals in a research report on Thursday, March 7th. Zacks Investment Research raised Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a research report on Saturday, January 19th. Finally, HC Wainwright reissued a “buy” rating on shares of Zynerba Pharmaceuticals in a research report on Monday, March 18th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $18.52.

The stock has a market capitalization of $278.40 million, a price-to-earnings ratio of -5.07 and a beta of 5.62.



Zynerba Pharmaceuticals (NASDAQ:ZYNE) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.02. On average, equities research analysts forecast that Zynerba Pharmaceuticals Inc will post -2.1 EPS for the current fiscal year.

Several hedge funds have recently bought and sold shares of ZYNE. Virtu Financial LLC purchased a new stake in shares of Zynerba Pharmaceuticals during the 4th quarter worth about $40,000. Two Sigma Investments LP purchased a new position in Zynerba Pharmaceuticals in the 4th quarter valued at about $120,000. Bernardo Wealth Planning LLC lifted its stake in Zynerba Pharmaceuticals by 5.3% in the 1st quarter. Bernardo Wealth Planning LLC now owns 25,419 shares of the company’s stock valued at $138,000 after buying an additional 1,278 shares in the last quarter. Jane Street Group LLC lifted its stake in Zynerba Pharmaceuticals by 44.6% in the 3rd quarter. Jane Street Group LLC now owns 35,555 shares of the company’s stock valued at $290,000 after buying an additional 10,967 shares in the last quarter. Finally, Campbell Capital Management Inc. purchased a new position in Zynerba Pharmaceuticals in the 4th quarter valued at about $510,000. 12.93% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “Zynerba Pharmaceuticals (ZYNE) Hits New 12-Month High at $13.63” was first published by Dakota Financial News and is the property of of Dakota Financial News. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://dakotafinancialnews.com/2019/05/14/zynerba-pharmaceuticals-zyne-hits-new-12-month-high-at-13-63.html.

Zynerba Pharmaceuticals Company Profile (NASDAQ:ZYNE)

Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company is developing Zygel, a transdermal cannabidiol gel, which is in Phase II clinical trial for treating children and adolescent patients with developmental and epileptic encephalopathies; is in Phase II/III clinical trial to treat children and adolescent patients with fragile X syndrome; and is in Phase II clinical trial for treating children and adolescent patients with autism spectrum disorder.

Recommended Story: What is a front-end load?

Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.